Myeloma News and Research

RSS

Risk of specific genetic translocation is higher in patients of African ancestry, shows study

Multiple myeloma is a plasma cell cancer that is more common in patients of African American descent than of European American descent.

10 Dec 2019

Combination therapy is safe and effective for older patients diagnosed with acute lymphoblastic leukemia

A study led by The University of Texas MD Anderson Cancer Center showed that treatment combining lower doses of chemotherapy with the monoclonal antibody inotuzumab ozogamicin (INO), with or without the drug blinatumomab, is safe and effective in patients over 60 years of age who were newly diagnosed with a high-risk form of acute lymphoblastic leukemia (ALL) known as Philadelphia chromosome-negative ALL.

10 Dec 2019

Relapsed mantle cell lymphoma patients may benefit from CAR T-cell therapy

A one-year follow-up study led by The University of Texas MD Anderson Cancer Center revealed a majority of patients with mantle cell lymphoma resistant to prior therapies may benefit from treatment with CD19-targeting chimeric antigen receptor (CAR) T-cell therapy.

9 Dec 2019

$Novel agent opens up new treatment option for patients with refractory myeloma$

Novel agent opens up new treatment option for patients with refractory myeloma

A novel agent called Selinexor has opened up new options for the treatment of patients with refractory myeloma. This was the conclusion of a major international clinical trial in which also the Karl Landsteiner University of Health Sciences in Krems, Austria participated.

6 Dec 2019

Cancer patients have higher risk of cardiovascular death

A new study says that over 10% of patients with cancer die of unrelated cardiovascular disease (CVD) rather than their cancers.

25 Nov 2019

Risk of death from heart disease found to be higher in cancer patients

More than one in ten cancer patients do not die from their cancer but from heart and blood vessel problems instead, according to new research published in the European Heart Journal today. For some cancers, like breast, prostate, endometrial, and thyroid cancer, around half will die from cardiovascular disease (CVD).

25 Nov 2019

Fosun Pharma, MimiVax to jointly develop and commercialize SurVaxM therapy in U.S.

The inventors of a new and unique cancer immunotherapy developed at Roswell Park Comprehensive Cancer Center have announced a major step forward with that therapy, known as SurVaxM. MimiVax LLC principals Robert Fenstermaker, MD, and Michael Ciesielski, PhD, have announced that the company, spun off from Roswell Park in 2012, has entered into a China-exclusive licensing agreement for SurVaxM with Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd., a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical Co. Ltd. based in Shanghai, China.

20 Nov 2019

New device separates malignant plasma cells from normal ones

Multiple myeloma is a type of blood cancer in which malignant plasma cells, a type of white blood cell, accumulate in the bone marrow.

19 Nov 2019

New microfluidics device detects malignant multiple myeloma cells in blood

Scientists have developed a microfluidics device that could be used for the detection or monitoring of multiple myeloma.

19 Nov 2019

Gene-editing technique CRISPR trialed for first time as cancer treatment

The go-ahead has been given for the first trials using CRISPR as an alternative therapy for treating cancer.

6 Nov 2019

Chiral interactions could be leveraged to improve the performance of drug-delivery nanoparticles

MIT engineers have shown that they can enhance the performance of drug-delivery nanoparticles by controlling a trait of chemical structures known as chirality -- the "handedness" of the structure.

6 Nov 2019

Researchers discover new process of antitumor response of NK cells in myeloma

NK cells mean Natural Killer cells. They are part of the innate immune system. They are known primarily for their ability to recognize and kill tumor cells, cells infected by viruses and bacteria, or dying by apoptosis. Although evidence about their antitumoral capacity, how this activity occurred remained unknown.

5 Nov 2019

Study: Unusually frequent hospital visit can help spot people at risk of myeloma

A condition that can progress to myeloma could be identified in patients by their unusually frequent hospital visits, according to research presented at the 2019 NCRI Cancer Conference.

3 Nov 2019

Three UCLA researchers receive multimillion-dollar grant from state's stem cell agency

Three researchers at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA have received awards totaling more than $18 million from the California Institute for Regenerative Medicine, the state's stem cell agency.

31 Oct 2019

NCCN publishes new clinical practice guidelines for hematopoietic cell transplantation

Today, the National Comprehensive Cancer Network published new NCCN Clinical Practice Guidelines in Oncology for Hematopoietic Cell Transplantation, also known as stem cell transplant or historically as bone marrow transplant.

30 Oct 2019

Cancer drug may delay progression of bone and other myeloma-related organ damage

The largest randomized trial in asymptomatic patients with smoldering multiple myeloma suggests that lenalidomide, a cancer drug, may delay the onset of bone and other myeloma-related organ damage.

28 Oct 2019

Phase 2 clinical trial of CAR T-cell therapy starts at Atlantic Health System

Atlantic Health System is treating patients in a new Phase 2 clinical trial of CAR T-cell therapy at Morristown Medical Center. A select number of sites across the U.S. are involved in this study, which is done on an outpatient basis.

25 Oct 2019

The ONCOMMUN Program will receive €900,000 grant to promote well-being in cancer

The ONCOMMUN Program will receive a grant worth 900,000 euros for 2019-2020 by the European Institute of Innovation & Technology which will be used to promote well-being in cancer through new technologies.

11 Oct 2019

New screening test detects 20 types of cancer

Researchers from the Dana-Farber Cancer Institute have developed a new blood test that would accurately determine the presence of several types of cancers. The results of their multi-centre clinical trial to prove the effectiveness of their test was presented by the researchers at the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain, on the 28th of September 2019.

30 Sep 2019

New blood test shows ability to accurately detect numerous types of cancer

A new blood test in development has shown ability to screen for numerous types of cancer with a high degree of accuracy, a trial of the test shows.

28 Sep 2019